Stay updated with breaking news from Lymphoma Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- The Leukemia & Lymphoma Society (LLS) recognized and celebrated the outstanding contributions of six LLS-funded scientific investigators for...
RYE BROOK, N.Y., Dec. 14, 2022 /PRNewswire/ -- The Leukemia & Lymphoma Society (LLS) recognized and celebrated the outstanding contributions of si...
A targeted therapy for children with high-risk Hodgkin lymphoma (HL) was shown to significantly reduce relapse rates when tested in a large multicenter clinical trial conducted by the Children's Oncology Group (COG) and led by pediatric oncologists at Roswell Park Comprehensive Cancer Center, Children's Healthcare of Atlanta and Winship Cancer Institute of Emory University. By combining the targeted antibody-drug conjugate (ADC) brentuximab vedotin (BV) with the standard chemotherapy regimen, children were 10% less likely to relapse.
Buffalo, NY, and Atlanta, GA (PRWEB) November 02, 2022 -- BUFFALO, N.Y., and ATLANTA, Ga. — A targeted therapy for children with high-risk Hodgkin lymphoma
/PRNewswire/ -- The global leader in the fight against blood cancers, The Leukemia & Lymphoma Society (LLS), announced the launch of its Pediatric Acute...